The Journal of clinical endocrinology and metabolism最新文献

{"title":"Sex steroids and women's physical performance in midlife: Findings from the Menarche-to-PreMenopause Study.","authors":"Leticia W Ribeiro, Jenny Doust, Gregore I Mielke, Jenny A Visser, Gita D Mishra","doi":"10.1210/clinem/dgaf528","DOIUrl":"https://doi.org/10.1210/clinem/dgaf528","url":null,"abstract":"<p><strong>Context: </strong>Sex steroids regulate various processes in reproductive and non-reproductive systems, but relationships with physical function in females remain unclear.</p><p><strong>Objective: </strong>To investigate the associations of oestrogen, androgen, and sex hormone-binding globulin (SHBG) concentrations with performance-based physical function tests among middle-aged Australian women.</p><p><strong>Methods: </strong>Cross-sectional study with 484 women aged 44.6 ± 1.6 years from the Menarche-to-PreMenopause Study. Oestrogen (oestrone and oestradiol) and androgen (testosterone, DHT, and DHEA) concentrations were measured using liquid chromatography-mass spectrometry. SHBG was measured with immunoassays. Performance was measured by handgrip strength, chair rise and standing balance tests. Participants in the lowest tertile were classified as \"low performance\". Linear and logistic regression models were used to evaluate associations between log-transformed sex hormones and performance.</p><p><strong>Results: </strong>In the linear regression analysis, a negative association between oestrone concentrations and chair rise performance was observed after minimal adjustment for clinic location, age, height, and weight (fully adj. coef. -0.2; 95% CI: -0.3, -0.002). Results from the logistic regression showed 30% lower odds of worse standing balance with higher DHT (95% CI: 0.6, 0.9) and SHBG concentrations (95% CI: 0.5, 0.9). No other significant associations were observed in the fully adjusted models.</p><p><strong>Conclusion: </strong>Findings from this study suggest that oestrone was negatively associated with chair rise performance, whereas DHT and SHBG concentrations were positively associated with standing balance performance among Australian women in their forties. While sex steroids seem to be closely related to performance, other factors, such as age and body size, may influence those associations.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of SGLT2 inhibitors on glomerular filtration in type 1 diabetes.","authors":"Michael W Holliday, Sankar D Navaneethan","doi":"10.1210/clinem/dgaf535","DOIUrl":"https://doi.org/10.1210/clinem/dgaf535","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence applications in thyroid cancer care.","authors":"Nikita Pozdeyev, Samantha L White, Caitlin C Bell, Bryan R Haugen, Johnson Thomas","doi":"10.1210/clinem/dgaf530","DOIUrl":"https://doi.org/10.1210/clinem/dgaf530","url":null,"abstract":"<p><strong>Context: </strong>Artificial intelligence (AI) has created tremendous opportunities to improve thyroid cancer care.</p><p><strong>Evidence acquisition: </strong>We used the \"artificial intelligence thyroid cancer\" query to search the PubMed database until May 31, 2025. We highlight a set of high-impact publications selected based on technical innovation, large generalizable training datasets, and independent and/or prospective validation of AI.</p><p><strong>Evidence synthesis: </strong>We review the key applications of AI for diagnosing and managing thyroid cancer. Our primary focus is on using computer vision to evaluate thyroid nodules on thyroid ultrasound, an area of thyroid AI that has gained the most attention from researchers and will likely have a significant clinical impact. We also highlight AI for detecting and predicting thyroid cancer neck lymph node metastases, digital cyto- and histopathology, large language models for unstructured data analysis, patient education, and other clinical applications. We discuss how thyroid AI technology has evolved and cite the most impactful research studies. Finally, we balance our excitement about the potential of AI to improve clinical care for thyroid cancer with current limitations, such as the lack of high-quality, independent prospective validation of AI in clinical trials, the uncertain added value of AI software, unknown performance on non-papillary thyroid cancer types, and the complexity of clinical implementation.</p><p><strong>Conclusion: </strong>AI promises to improve thyroid cancer diagnosis, reduce healthcare costs and enable personalized management. High-quality, independent prospective validation of AI in clinical trials is lacking and is necessary for the clinical community's broad adoption of this technology.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polycystic Ovary Syndrome and Sleep Disturbance in Postmenopausal Women: Study of Women's Health Across the Nation.","authors":"Snigdha Alur-Gupta, Fangbai Sun, Heping Zhang, Carol A Derby, Howard M Kravitz, Genevieve Neal-Perry, Leslie M Swanson, Wendy S Vitek, Nanette Santoro, Mary D Sammel","doi":"10.1210/clinem/dgaf529","DOIUrl":"https://doi.org/10.1210/clinem/dgaf529","url":null,"abstract":"<p><strong>Context: </strong>Reproductive age women with polycystic ovarian syndrome (PCOS) are more likely to have sleep apnea and experience sleep disturbances. Since sleep disturbances are known to worsen with age and to impact multiple health outcomes, the sleep experience of postmenopausal women with PCOS is of interest.</p><p><strong>Objective: </strong>Determine if postmenopausal women with PCOS have persistently worse subjective and objective measures of sleep disturbance.</p><p><strong>Design: </strong>Longitudinal and cross-sectional analyses.</p><p><strong>Setting: </strong>Study of Women's Health Across the Nation (SWAN).</p><p><strong>Participants: </strong>Women with a history of signs/symptoms of PCOS compared to those without.</p><p><strong>Interventions: </strong>None.</p><p><strong>Main outcome measures: </strong>Longitudinal changes in self-reported sleep disturbances (trouble falling asleep, waking up several times at night and waking up earlier than planned), from baseline to 15th SWAN follow-up visit. Actigraphic assessed and self-reported measures at Visit 15 (20-22 years from start of study).</p><p><strong>Results: </strong>83 women with PCOS were compared to 1977 women without PCOS. Longitudinal trends in self-reported sleep disturbance prevalence in women with PCOS plateaued whereas those without PCOS increased through post-menopause. In adjusted longitudinal analyses, women with PCOS who were naturally postmenopausal were significantly less likely to report sleep disturbances compared to those without PCOS. At Visit 15, sleep measures assessed via actigraphy and self-report did not differ between those with PCOS and those without.</p><p><strong>Conclusions: </strong>Longitudinal patterns of sleep disturbances differ between those with and without PCOS. In women with PCOS the prevalence of sleep disturbance remained relatively stable into postmenopause rather than increasing.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: \"Estimating Net Bone Formation Relative to Resorption Using Reference Bone Turnover Markers\".","authors":"","doi":"10.1210/clinem/dgaf490","DOIUrl":"https://doi.org/10.1210/clinem/dgaf490","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the Intimate Relationship of Adiposity to Polycystic Ovary Syndrome.","authors":"Robert L Rosenfield, Daniel A Dumesic","doi":"10.1210/clinem/dgaf527","DOIUrl":"https://doi.org/10.1210/clinem/dgaf527","url":null,"abstract":"<p><p>This review examines the nature of the relationship of increased adiposity to hyperandrogenic oligo-anovulatory polycystic ovary syndrome (PCOS). Most PCOS results from a \"functionally typical\" form of ovarian hyperandrogenism characterized by a unique pattern of ovarian steroidogenic hyperresponsiveness to gonadotropin stimulation that seems explainable by gene variants that cause over-expression of an activating variant of DENND1A (differentially expressed in normal and neoplastic development). However, one-third of PCOS is \"functionally atypical\", lacking this ovarian response. These two forms of PCOS share clinical traits with the respective \"reproductive\" and \"metabolic\" subtypes of PCOS that have been recently distinguished by cluster analysis, with DENND1A gene variants present in significantly more of the former. This review suggests that severe adiposity causes \"metabolic/functionally atypical\" PCOS by enhancing ovarian steroidogenesis through hyperinsulinism and adipose- and gut-dependent proinflammatory adipokines in genetically predisposed individuals, plus amplifying the ability of adipose tissue to generate testosterone and adrenal-derived 11ß-hydroxytestosterone from circulating precursors. This review furthermore indicates that preferential abdominal fat accumulation, often subclinical, is a central feature of PCOS that also affects metabolic function. The hyperandrogenic environment created within adipose by adiposity-dependent and independent insulin-resistant hyperinsulinism, intra-adipose steroidogenesis, and PCOS-related hyperandrogenemia also appears to restrict the capacity of subcutaneous adipose to safely store fat, predisposing to ectopic fat deposition and lipotoxicity with weight gain. We conclude that excess total and/or abdominal fat seems to be a nearly constant feature of PCOS, either as the cause of hyperandrogenism or as the result of hyperandrogenism contributing to the adipogenic endocrine milieu.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statins do not affect bone anabolism in older women treated with teriparatide.","authors":"Cecilia Oliveri, Anastasia Xourafa, Nunziata Morabito, Agostino Gaudio, Ilaria Politi, Peter Schwartz, Salvatore Minisola, Antonino Catalano","doi":"10.1210/clinem/dgaf523","DOIUrl":"https://doi.org/10.1210/clinem/dgaf523","url":null,"abstract":"<p><strong>Context: </strong>Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, HMG-CoA reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.</p><p><strong>Objective: </strong>To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.</p><p><strong>Methods: </strong>This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25,000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase (ALP), osteocalcin (OCN), and C-terminal telopeptide of type I collagen (CTX)-were measured every six months.</p><p><strong>Results: </strong>Thirty patients were statin users and seventy-four were non-users. Statin users experienced lumbar spine BMD gain from 0.71±0.16 to 0.79±0.14 g/cm² (p=0.01), and a trend toward femoral neck improvement from 0.53±0.24 to 0.62±0.12 g/cm² (p=0.07). Non-users also showed lumbar spine BMD rise from 0.70±0.10 to 0.77±0.11 g/cm² (p=0.001), with no significant femoral neck BMD change from 0.60±0.11 to 0.58±0.15 g/cm² (p=0.5). At the end of the observation period, CTX levels were significantly lower in statin users compared to non-users (0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007). Conversely, no significant intergroup differences were observed for ALP and OCN throughout the observation period.</p><p><strong>Conclusion: </strong>Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, and it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-Racial Cytokine Profiling Reveals Immune Dysregulation not Chronic Inflammation in Polycystic Ovary Syndrome.","authors":"Gabriela Pacheco-Sanchez, Rebecca Herrera, Margareta D Pisarska, Ricardo Azziz, Dequina A Nicholas, Jessica L Chan","doi":"10.1210/clinem/dgaf524","DOIUrl":"https://doi.org/10.1210/clinem/dgaf524","url":null,"abstract":"<p><strong>Context: </strong>Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder often associated with chronic inflammation, but comprehensive characterization of immune markers across diverse patient populations is lacking.</p><p><strong>Objective: </strong>To determine whether PCOS exhibits a profile of chronic inflammation or immune dysregulation when analyzed across a diverse patient population.</p><p><strong>Design: </strong>Retrospective cross-sectional study of samples collected between 1987 and 2010 as part of the Androgen Excess Biorepository.</p><p><strong>Setting: </strong>Reproductive endocrinology clinics at the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, and Cedars-Sinai Medical Center (CSMC) in Los Angeles, California, where women and adolescents presented for evaluation of androgen excess.</p><p><strong>Patients: </strong>40 premenopausal women (20 with PCOS, 20 controls) aged 18-45 years, categorized by race (Black and White) and PCOS diagnosis. Participants were race, age, and BMI-matched.</p><p><strong>Main outcome measures: </strong>Fasted follicular phase plasma concentrations of CRP and 96 circulating immune markers, including IL-6, TNF-α, and IL-18, measured using a Milliplex Luminex xMAP assay.</p><p><strong>Results: </strong>PCOS patients showed significantly lower levels of circulating immune markers (p<0.05). Growth factors (VEGF-A, PDGF), pro-inflammatory cytokines (IL-8, TNF-α, IFN-γ), and several chemokines were reduced in PCOS patients, independent of race. Only IL-18 and CXCL16 showed statistically significant differences between Black and White women.</p><p><strong>Conclusions: </strong>This study challenges the prevailing notion of PCOS as a disorder of chronic low-grade inflammation, suggesting instead that immune suppression and impaired angiogenic signaling may be factors in PCOS pathophysiology, especially in non-obese patients. Further research with larger sample sizes and inclusion of metabolic metrics is needed to confirm these findings before they can be applied in clinical practice.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum anti-müllerian hormone as a biomarker of functional testicular reserve: a comparative analysis.","authors":"Edoardo Pozzi, Fausto Negri, Massimiliano Raffo, Alessandro Bertini, Christian Corsini, Luca Boeri, Marina Pontillo, Massimo Locatelli, Enrico Papaleo, Luca Pagliardini, Alessia d'Arma, Massimo Alfano, Francesco Montorsi, Andrea Salonia","doi":"10.1210/clinem/dgaf520","DOIUrl":"https://doi.org/10.1210/clinem/dgaf520","url":null,"abstract":"<p><strong>Study question: </strong>How do serum Anti-Müllerian hormone (AMH) levels differ among men with varying fertility statuses, and what is the relationship between AMH, spermatogenesis, and functional testicular reserve?</p><p><strong>Summary answer: </strong>Serum AMH levels were significantly lower in men with NOA compared to fertile controls and non-azoospermic infertile men. AMH correlated negatively with age and FSH, and positively with testicular volume and sperm concentration. After adjustment, AMH showed no independent association with sperm concentration.</p><p><strong>What is known already: </strong>AMH is produced by Sertoli cells and may serve as a biomarker of spermatogenesis, yet literature lacks comprehensive comparative analyses across male fertility conditions.</p><p><strong>Study design, size, duration: </strong>Cross-sectional study with 1,085 white-European non-Finnish men with confirmed fertility, primary infertility, or NOA.</p><p><strong>Participants/materials, setting, methods: </strong>Men with confirmed fertility (n=116), primary infertility (n=791), and NOA (n=178) underwent comprehensive hormonal and semen analyses per WHO 2010 criteria. Kruskal-Wallis and Chi-square tests were used for group comparisons. Correlations were assessed using Spearman's rank correlation. Multivariate linear regression models identified factors associated with AMH levels and sperm concentration.</p><p><strong>Main results and the role of chance: </strong>AMH levels were significantly lower in non-obstructive azoospermia versus fertile men and primary infertility 3.8 (1.6-7.2) vs. 5.1 (3.6-7.0) vs. 4.9 (3.0-7.8) ng/mL; p<0.001. AMH negatively correlated with age and FSH, positively with testicular volume and sperm concentration. Age, FSH, and testicular volume independently associated with AMH; FSH and testicular volume, not AMH, independently associated with sperm concentration.</p><p><strong>Limitations, reasons for caution: </strong>Cross-sectional design limits causality. Limited ethnic generalizability.</p><p><strong>Wider implications of the findings: </strong>AMH reflects Sertoli cell function and testicular status rather than directly influencing spermatogenesis, potentially serving as a complementary male fertility biomarker.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric and Sleep disorders in Patients with Non-Functional Adrenal Tumors.","authors":"Hadis Mirzaei, Jonatan D Lindh, Buster Mannheimer, Henrik Falhammar","doi":"10.1210/clinem/dgaf525","DOIUrl":"https://doi.org/10.1210/clinem/dgaf525","url":null,"abstract":"<p><strong>Context: </strong>An increase of psychiatric and sleep-related disorders could be hypothesized due to mild abnormal cortisol secretion in patients with non-functional adrenal tumors (NFATs).</p><p><strong>Objective: </strong>To investigate the risk of psychiatric and sleep disorders in individuals with NFATs.</p><p><strong>Methods: </strong>A national retrospective register-based study was conducted on patients diagnosed with NFATs 2005-2019 and controls, followed-up until death or 2019. Individuals diagnosed with adrenal hormone excess or previous malignancies were excluded. Follow-up commenced after 90 days of cancer-free survival following the NFAT diagnosis. Sensitivity analyses were performed on patients with acute appendicitis and gallbladder/biliary tract/pancreas disorders, and 180- and 365-day cancer-free survival. The primary study outcomes were the prevalence and incidence of psychiatric and/or sleep disorders after adjusting for sex, age, and socioeconomic factors. Secondary outcomes were psychiatric, sleep, substance abuse, mood, anxiety and stress-related, and psychotic disorders.</p><p><strong>Results: </strong>In total, 17,561 cases (60% women, median (IQR) age 65 (56-73) years) and 122,561 controls were included. Previous psychiatric and/or sleep disorders were more prevalent in patients diagnosed with NFATs compared to controls (odds ratio (OR) 2.11, 95%CI 2.03-2.19, adjusted OR 2.06, 95%CI 1.98-2.14). During the follow-up period (5.4 years (IQR 2.4-8.6)), the incidence of psychiatric and/or sleep disorders was higher in patients with NFATs than in controls (hazard ratio (HR) 1.92, 95%CI 1.83-2.02, adjusted HR 1.92, 95%CI 1.82-2.01). Similar increases were found in all secondary outcomes as well as in the same direction in all sensitivity analyses.</p><p><strong>Conclusion: </strong>NFAT was associated with an increased risk of psychiatric and sleep disorders.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}